Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Allogeneic anti-CD7 CAR-T cells (BEAM-201)
Allogeneic anti-CD7 CAR-T cells · 1 trial · 1 indication
The Maximum Tolerated Dose will be determined by measuring the incidence of dose limiting toxicities following administration of the product.
Frequency of Adverse events will be measured by evaluating the frequency and severity of treatment related adverse events following administration of Beam-201 Cells
| Arm | Type | Description |
|---|---|---|
| Dose Escalation Arm | EXPERIMENTAL | The dose escalation portion of the trial will use a standard "3+3" design to establish the recommended maximum tolerated dose of BEAM-201 cells. Three dose escalations of BEAM-201 are planned for the dose escalation phase, with one dose de-escalation level if needed. Should there be sufficient clinical response at lower doses (i.e. DL1 or DL2), then the sponsor and principal investigator may choose to forgo further dose escalation and proceed to dose expansion at the lower dose level. |
| Dose Expansion Arm | EXPERIMENTAL | If at least one dose level of the dose escalation phase is determined to be safe, the dose expansion phase of the trial will be opened to enrollment. |
| Name | Type | Description |
|---|---|---|
| Allogeneic anti-CD7 CAR-T cells (BEAM-201) | BIOLOGICAL | The investigational agent in this protocol is allogeneic anti-CD7 CART cells (BEAM-201). BEAM-201 is comprised of allogeneic anti-CD7 CAR-T cells edited by 4 gRNAs and a single mRNA encoding a CBE, then transduced with a lentiviral vector (LVV) encoding the anti-CD7 chimeric antigen receptor (CAR) molecule. |
Patients must meet all the following criteria to be eligible for enrollment into the study: 1. Patients (ages ≥ 18 years) or parent/legal guardians (for patients ages \< 18 years) must provide signed, written informed consent according to local IRB and institutional requirements. 2. Ages 0 to 29 ye...
Allogeneic anti-CD7 CAR-T cells are used for the treatment of T-Cell Acute Lymphoblastic Leukemia/Lymphoma. This investigational therapy is being studied in patients with relapsed or refractory disease. It is currently in Phase 1 clinical development and has not been approved by regulatory authorities.
Allogeneic anti-CD7 CAR-T cells target the CD7 protein, which is expressed on T-cell malignancies. The therapy is designed to recognize and eliminate cancer cells that display CD7, potentially offering a treatment option for T-Cell Acute Lymphoblastic Leukemia/Lymphoma.
Allogeneic anti-CD7 CAR-T cells are being developed by Beam Therapeutics Inc., a biotechnology company traded on NASDAQ under the ticker BEAM. The company is conducting clinical trials to evaluate this investigational cell therapy in patients with T-Cell Acute Lymphoblastic Leukemia/Lymphoma.
Allogeneic anti-CD7 CAR-T cells are in Phase 1 clinical development. This early-stage trial is currently recruiting participants to assess the safety and preliminary efficacy of the therapy in patients with relapsed or refractory T-Cell Acute Lymphoblastic Leukemia/Lymphoma. The drug is investigational and not yet approved.
Allogeneic anti-CD7 CAR-T cells are being evaluated in a Phase 1 clinical trial registered as NCT06934382. This study, titled 'Anti-CD7 CAR-T Cells in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia or Lymphoma,' is recruiting 33 participants in the United States and is open to patients of all ages.
Yes, Allogeneic anti-CD7 CAR-T cells are also known as BEAM-201. This alternative name is used by the developer, Beam Therapeutics Inc., to refer to the same investigational cell therapy being studied for T-Cell Acute Lymphoblastic Leukemia/Lymphoma.